Antimicrobial Agents and Chemotherapy · 2014 · 55 citations · 36 references
Veterinary MedicineInfectious DiseasesPharmacologyImmunopathologyImmunopharmacologyInflammationAntibacterial PharmacologyAntibacterial PharmacotherapyAntimicrobial TherapyCombination Antimicrobial TherapyInflammation In Infectious DiseaseSkin InfectionsInflammation In Infected WoundsInflammatory Tissue DamageNeutralizing Antibody EvasionSkin Infection TherapySkin Infection TreatmentSoft Tissue Infection PathogenesisSoft Tissue Infection TherapyStaphylococcal Infection Therapy
Alpha-toxin (AT) is a major virulence determinant in Staphylococcus aureus skin and soft tissue infection models. We previously demonstrated that prophylactic administration of 2A3, an AT-neutralizing monoclonal antibody (MAb), prevents S. aureus disease in a mouse dermonecrosis model by neutralizing AT-mediated tissue necrosis and immune evasion. In the present study, MEDI4893*, an affinity-optimized version of 2A3, was characterized for therapeutic activity in the dermonecrosis model as a single agent and in combination with two frontline antibiotics, vancomycin and linezolid. MEDI4893* postinfection therapy was found to exhibit a therapeutic treatment window similar to that for linezolid but longer than that for vancomycin. Additionally, when combined with either vancomycin or linezolid, MEDI4893* resulted in reduced tissue damage, increased neutrophil and macrophage infiltration and abscess formation, and accelerated healing relative to those with the antibiotic monotherapies. These data suggest that AT neutralization with a potent MAb holds promise for both prophylaxis and adjunctive therapy with antibiotics and may be a valuable addition to currently available options for the treatment of S. aureus skin and soft tissue infections.
36
Differential Roles of Macrophages in Diverse Phases of Skin Repair
Tina Lucas, Ari Waisman, Rajeev Ranjan et al. · The Journal of Immunology · 2010 · 1.2K citations · Full text